Dendreon News

Dendreon had better pull something amazing out of the hat when it gets the results of its "Impact" study on Provenge , the drug it's developing for prostate cancer - because investors are already guessing that ...

Main Category: Prostate / Prostate Cancer Also Included In: Clinical Trials / Drug Trials ; Pharma Industry / Biotech Industry Article Date: 24 Jul 2008 - 2:00 PDT Dendreon Corporation announced that it expects ...

Main Category: Prostate / Prostate Cancer Also Included In: Urology / Nephrology ; Clinical Trials / Drug Trials ; Pharma Industry / Biotech Industry Article Date: 17 Jul 2008 - 1:00 PDT Dendreon Corporation ...

We all know the legends of growth investing. But I submit that growth grabbers can learn as much from a single phrase from Warren Buffett -- the patron saint of value investing -- as they might from the ...

Starbucks enters agreement to settle T-Mobile lawsuit Starbucks Corp. said Wednesday that it has entered a "memorandum of understanding" to settle a lawsuit filed against it last week by Bellevue-based cellular ...

Dendreon Corporation today announced that Greg Schiffman, chief financial officer of Dendreon, will present a company update at the Needham 7th Annual Biotechnoloy and Medical Technology Conference in New York ...

The controversy over prostate cancer treatment Provenge came to a head in the Seattle area Friday, as roughly 15 people rallied in front of Westlake Center and outside the FDA offices in Bothell, urging the FDA ...

Puget Sound Business Journal A rally in support of Dendreon Corp. 's Provenge prostate cancer drug is set for May 30, with protests scheduled for nine U.S. cities.

They don't know when, exactly, but millions of investors are worried they're about to get wiped out.

“This is a milestone of noteworthy significance”

MediQuest Therapeutics said Monday that it requested approval by federal regulators of its experimental therapy to treat Raynaud's disease. via Seattle Times

Packeteer, Inc. , Dendreon Corp. and ShengdaTech, Inc. are among the most actively traded companies in Monday's pre-market trading among those with market capitalizations under $750 million. via All Stories

On April 3, Seattle's Dendreon Corp. said it had raised $46 million by selling 8 million shares and an additional 8 million warrants of its stock to an unnamed institutional investor. via Seattle Post-Intelligencer

“This is probably not an uncommon pick. The odds this company survives (at least insofar as that means a non-zero value for the stock) are at best 50-50.”

Successful investing requires you to think independently and stick to your convictions. via The Motley Fool

Novatel Wireless, Inc. , Sigma Designs, Inc. and Dendreon Corp. are among the most actively traded companies in Tuesday's pre-market trading among those with market capitalizations under $750 million. via All Stories

There are very few positive surprises in drug-company investing. Sure, companies like Dendreon can get a positive surprise from a review panel and then a negative surprise from the FDA , but I'm talking about ... via Fool.com

“Everyone dumped on me. They accused me of being short the stock and characterized my analysis as perverted.”

In Homer's The Odyssey , Odysseus plugged his crew's ears with wax to tune out the Sirens' song. via The Motley Fool

AGEN / DNDN The tiny biotechnology company Antigenics Inc said on Tuesday that it has won approval to market its kidney cancer vaccine, Oncophage, in Russia, making it the only cancer vaccine available in the ... via Seeking Alpha

“This certification allows us to continue to expand our offerings to our core merchant base and allows us to expand that base greatly.”

Are you a public company looking for exposure? Contact RealPennies.com - 1.800.940.6559 For more info: http://dndn.realpennies.com Dendreon Corporation announced that it has entered into a definitive agreement ... via M2.com

Two days after rival Cell Genesys inked a deal with a pharmaceutical company that will give it an upfront payment of $50 million, Seattle's Dendreon Corp. via Seattle Post-Intelligencer

Biotech hotshot Dendreon has a new private institutional investor in its corner---and it is not saying who. via Forbes.com